The puzzling thing about these positive readouts is they are only worth 3 or 4 cents...
Think about what it's going to be worth when the medical community and desperate patients discover the tremendous therapeutic potential of PLX-R18.
Think about all the circumstances where hematological support is indicated, from chemotherapy, radiation treatments and the battlefield (or civilian casualties in a dirty bomb attack).
We're talking about multi-billion dollar markets, and a meteoric rise for Pluristem. Every new piece of data, from diverse medical and scientific sources adds to the probability of this treatment proving itself to be effective (and we just got one more !)
The fact that the market does not see it at this point is advantageous for those of us who discovered this incredible company recently. (sorry about the "DEAD MONEY" people, ten years ago was definitely way too early to invest, so I can understand the anger and bitterness, though not the need to inflict it on this board).
Anyway, who ever said that the market is efficient, it's not, that's why every now and then, you get lucky and find a Pluristem while it's still very affordable.